{"filings":[{"id":833436,"accession_number":"0001193125-26-255396","cik":1582313,"company_name":"Xenon Pharmaceuticals Inc.","ticker":"XENE","form_type":"8-K","filed_at":"2026-06-03T20:02:22+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Xenon shareholders approve 2026 equity plan, elect directors at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Shareholders approved the 2026 Equity Incentive Plan: 58.6M for, 27.6M against, 842K abstain.","New plan authorizes 4.4M new shares plus up to 14.72M shares from the prior plan (subject to expiry/forfeiture).","All 8 director nominees elected; say-on-pay approved (82.2M for, 4.8M against), with 1-year frequency chosen.","PricewaterhouseCoopers reappointed as auditor (90.4M for, 27.7K withheld); auditor remuneration authority approved.","Voter turnout: 90.4M shares (93.54% of eligible) were represented at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":5224770000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93847,"accession_number":"0001193125-26-211843","cik":1582313,"company_name":"Xenon Pharmaceuticals Inc.","ticker":"XENE","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Xenon reports positive Phase 3 X-TOLE2 data for azetukalner; NDA submission planned Q3 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Phase 3 X-TOLE2 met primary endpoint: median percent change in monthly FOS -53.2% (25mg) and -34.5% (15mg) vs -10.4% placebo (p<0.0001).","NDA submission to FDA planned Q3 2026 based on X-TOLE2 and X-TOLE data.","Cash and marketable securities $1.34B as of March 31; cash runway into 2029. Net loss $102.3M for Q1 2026.","Enrollment ongoing for additional Phase 3 studies: X-TOLE3 (FOS), X-ACKT (PGTCS), X-NOVA2/3 (MDD), X-CEED (BPD); X-NOVA2 topline H1 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.17,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":5224770000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93846,"accession_number":"0001193125-26-152834","cik":1582313,"company_name":"Xenon Pharmaceuticals Inc.","ticker":"XENE","form_type":"8-K","filed_at":"2026-04-13T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Xenon increases inducement equity plan share reserve from 900k to 1.175M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amended 2025 Inducement Plan to raise maximum shares reserved from 900,000 to 1,175,000, a 30.6% increase.","Shares are reserved exclusively for inducement grants (nonstatutory options, RSUs, etc.) to new employees.","Amendment approved by independent directors; shareholder approval not obtained per Nasdaq Rule 5635(c)(4).","Plan amended effective April 7, 2026; full text filed as Exhibit 10.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":5224770000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105792,"accession_number":"0001193125-26-106144","cik":1582313,"company_name":"Xenon Pharmaceuticals Inc.","ticker":"XENE","form_type":"8-K","filed_at":"2026-03-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Xenon Pharma sets 2026 annual meeting for June 2; record date April 7","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual meeting scheduled for June 2, 2026.","Record date for notice and voting is April 7, 2026.","Company will use notice-and-access for both registered and non-registered investors.","Only common shares are entitled to vote at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":5224770000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105791,"accession_number":"0001193125-26-104199","cik":1582313,"company_name":"Xenon Pharmaceuticals Inc.","ticker":"XENE","form_type":"8-K","filed_at":"2026-03-12T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Xenon Pharmaceuticals raises $707.7M in public offering of common shares and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offered 12.2M common shares at $57.00 plus pre-funded warrants for 877,194 shares at $56.9999 each.","Underwriters exercised option to purchase an additional 1.7M common shares in full.","Net proceeds of approximately $707.7 million after underwriting discounts and estimated expenses.","Offering closed on March 12, 2026; warrants have $0.0001 exercise price and are immediately exercisable.","Lead underwriters include J.P. Morgan, Jefferies, TD Securities, Stifel, RBC Capital Markets, and William Blair."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":5224770000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105790,"accession_number":"0001193125-26-097577","cik":1582313,"company_name":"Xenon Pharmaceuticals Inc.","ticker":"XENE","form_type":"8-K","filed_at":"2026-03-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Xenon Phase 3 X-TOLE2 azetukalner meets primary endpoint; NDA submission Q3 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Primary endpoint MPC: 25mg -53.2% vs placebo -10.4% (p<0.000000000006); placebo-adjusted -42.7%, outperforming Phase 2b.","Key secondary RR50: 54.8% (25mg) vs 20.8% placebo (p=0.00000008).","Safety consistent: most common TEAEs dizziness (20.5%), headache (8.8%), somnolence (8.8%), fatigue (7.6%).","NDA submission to FDA planned Q3 2026 for focal onset seizures.","Data to be presented as Late Breaking Science at AAN Annual Meeting in April 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":5224770000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105789,"accession_number":"0001193125-26-082520","cik":1582313,"company_name":"Xenon Pharmaceuticals Inc.","ticker":"XENE","form_type":"8-K","filed_at":"2026-02-27T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Xenon files $400M ATM equity prospectus supplement; $291M already sold under prior program","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed prospectus supplement to register up to $400M of common shares for at-the-market (ATM) sales.","Prior ATM sales total $291,084,564 as of filing date; prior program terminated.","Sales agents are Jefferies and Stifel; shares issuable under Sales Agreement dated Aug 2020 as amended.","Registration statement automatically effective on Form S-3 filed Aug 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5224770000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105788,"accession_number":"0001193125-26-076530","cik":1582313,"company_name":"Xenon Pharmaceuticals Inc.","ticker":"XENE","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Xenon reports 2025 net loss of $345.9M; Phase 3 X-TOLE2 data expected in March 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $345.9M in 2025 vs $234.3M in 2024; R&D expense rose to $300.9M on azetukalner Phase 3 trials.","Pro forma cash $716M (incl. $130M ATM in Q1 2026) extends runway into H2 2027.","Phase 3 X-TOLE2 topline data for azetukalner in focal onset seizures due first half of March 2026.","NDA submission for azetukalner in FOS planned H2 2026; 5 additional Phase 3 studies in epilepsy and depression enrolling.","Early-stage pipeline: Phase 1 data for XEN1701 (NaV1.7) and XEN1120 (KV7) pain candidates expected in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.36,"consensus_revenue_estimate":null,"consensus_revenue_actual":7500000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5224770000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122073,"accession_number":"0001193125-25-303862","cik":1582313,"company_name":"Xenon Pharmaceuticals Inc.","ticker":"XENE","form_type":"8-K","filed_at":"2025-12-01T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Xenon Pharma amends inducement plan, increases share reserve to 900,000","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amended 2025 Inducement Plan on Nov 24, 2025, increasing share reserve from 775,000 to 900,000 common shares.","Plan is exclusively for inducing new employees or rehires after a bona fide interruption of employment.","No shareholder approval sought under Nasdaq Listing Rule 5635(c)(4); plan meets inducement grant rules.","Awards include nonstatutory stock options, SARs, restricted stock units, restricted stock, and performance awards."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":5224770000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122072,"accession_number":"0001193125-25-262519","cik":1582313,"company_name":"Xenon Pharmaceuticals Inc.","ticker":"XENE","form_type":"8-K","filed_at":"2025-11-03T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Xenon Q3 net loss $90.9M, Phase 3 FOS study fully enrolled, new CFO appointed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $90.9M (vs $62.8M Q3 2024) on higher R&D spend; R&D expenses $77.1M (vs $57.0M).","Phase 3 X-TOLE2 FOS study completed enrollment (380 patients); topline data expected early 2026.","Phase 3 MDD (X-NOVA2/3) and BPD (X-CEED) studies continue recruiting; Phase 1 Nav1.7 and Kv7 studies underway.","Tucker Kelly appointed CFO to lead finance strategy ahead of azetukalner launch.","Cash $555.3M as of Sept 30, 2025; runway into 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":7500000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5224770000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122070,"accession_number":"0001193125-25-242583","cik":1582313,"company_name":"Xenon Pharmaceuticals Inc.","ticker":"XENE","form_type":"8-K/A","filed_at":"2025-10-17T23:59:59+00:00","items":["8.01","9.01","5.02"],"status":"ready","headline":"Xenon names Tucker Kelly CFO with $540k salary, 225k options, 30k RSUs","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Tucker Kelly appointed CFO effective Oct 15, 2025; replaces interim CFO Ian Mortimer who remains CEO.","Kelly's base salary $540k; eligible for annual incentive up to 45% of base.","Granted inducement option for 225k shares at $41.90 (Oct 15 close) vesting over 4 years.","Granted 30k RSUs vesting 25% annually over 4 years.","Kelly previously CFO of Deciphera, led commercial transition; will support azetukalner launch."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5224770000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122071,"accession_number":"0001193125-25-241546","cik":1582313,"company_name":"Xenon Pharmaceuticals Inc.","ticker":"XENE","form_type":"8-K","filed_at":"2025-10-16T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Xenon appoints Tucker Kelly as CFO; grants 225K options, 30K RSUs","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Tucker Kelly named CFO effective Oct 15, 2025; previously CFO at Deciphera (acquired by Ono for $2.4B).","Annual base salary $540K; eligible for incentive up to 45% of base.","One-time inducement grant: options for 225K shares at $41.90 (closing price Oct 15).","One-time grant of 30,000 RSUs; both options and RSUs vest over 4 years.","Interim CFO Ian Mortimer steps down but remains President & CEO as lead candidate azetukalner enters Phase 3."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5224770000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138777,"accession_number":"0000950170-25-106529","cik":1582313,"company_name":"Xenon Pharmaceuticals Inc.","ticker":"XENE","form_type":"8-K","filed_at":"2025-08-11T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Xenon Q2 net loss $84.7M; azetukalner Phase 3 X-TOLE2 enrollment complete, topline early 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $84.7M vs $57.9M Q2 2024; R&D expenses rose to $75.0M from $49.7M on azetukalner trials.","Phase 3 X-TOLE2 (focal seizures) patient recruitment complete; topline data expected early 2026.","Phase 1 studies underway for XEN1120 (Kv7) and XEN1701 (Nav1.7) pain candidates.","Darren Cline appointed Chief Commercial Officer to lead commercial build for azetukalner launch.","Cash $624.8M as of June 30, 2025; funding expected into 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.9,"consensus_revenue_estimate":null,"consensus_revenue_actual":7500000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5224770000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138776,"accession_number":"0000950170-25-093996","cik":1582313,"company_name":"Xenon Pharmaceuticals Inc.","ticker":"XENE","form_type":"8-K","filed_at":"2025-07-03T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Xenon CFO Sherry Aulin resigns; CEO Ian Mortimer appointed interim CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Sherry Aulin resigned as CFO, effective June 30, 2025.","Ian Mortimer (President & CEO) appointed interim CFO effective June 30, 2025, serving as principal financial and accounting officer.","No change to Mortimer's compensation in connection with the appointment.","Mortimer's background previously disclosed in the April 24, 2025 proxy statement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":5224770000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156230,"accession_number":"0000950170-25-082494","cik":1582313,"company_name":"Xenon Pharmaceuticals Inc.","ticker":"XENE","form_type":"8-K","filed_at":"2025-06-05T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Xenon Pharmaceuticals holds 2025 Annual Meeting; all director nominees elected","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 8 director nominees elected with over 64M votes each; broker non-votes of 2.2M.","Advisory say-on-pay passed with 67.3M for, 2.1M against, 0.5M abstain.","Appointment of PricewaterhouseCoopers LLP as auditor approved (72.0M for, 34K withheld).","Auditor remuneration authority approved (72.0M for, 25K against, 11K abstain).","Approximately 94.1% of outstanding common shares voted at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":5224770000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156229,"accession_number":"0000950170-25-069183","cik":1582313,"company_name":"Xenon Pharmaceuticals Inc.","ticker":"XENE","form_type":"8-K","filed_at":"2025-05-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Xenon Q1 net loss $65.0M; X-TOLE2 topline data shifted to early 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $65.0M (vs $47.9M Q1 2024) on higher R&D spend of $61.2M; revenue $7.5M from Neurocrine milestone.","Cash and securities $691.1M (down from $754.4M Dec 2024); cash runway into 2027.","Phase 3 X-TOLE2 FOS study recruitment to complete in months; topline data now expected early 2026 (modest shift).","Phase 3 MDD (X-NOVA3) and bipolar depression studies on track to initiate mid-2025.","Phase 1 started for XEN1120 (Kv7); IND for XEN1701 (Nav1.7) expected Q3 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.83,"consensus_revenue_estimate":null,"consensus_revenue_actual":7500000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5224770000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174689,"accession_number":"0000950170-25-040381","cik":1582313,"company_name":"Xenon Pharmaceuticals Inc.","ticker":"XENE","form_type":"8-K","filed_at":"2025-03-17T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Xenon Pharmaceuticals sets 2025 annual meeting for June 4, record date April 7","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual meeting of shareholders scheduled for June 4, 2025.","Record date for notice and voting is April 7, 2025.","Common shares are the only securities entitled to vote.","Issuer will use notice-and-access for both registered and non-registered investors.","Issuer will pay for distribution of materials to objecting beneficial owners."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.0,"calibrated_materiality_score":0.0,"market_cap_usd":5224770000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174688,"accession_number":"0000950170-25-033653","cik":1582313,"company_name":"Xenon Pharmaceuticals Inc.","ticker":"XENE","form_type":"8-K","filed_at":"2025-03-05T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Xenon Pharmaceuticals dismisses KPMG, appoints PwC as independent auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Audit Committee dismissed KPMG as independent registered public accounting firm on March 3, 2025.","No disagreements or reportable events with KPMG during 2024, 2023, or interim period through March 3, 2025.","Audit Committee approved engagement of PricewaterhouseCoopers LLP for fiscal year ending Dec 31, 2025.","No prior consultations with PwC regarding accounting principles or audit scope during the two most recent fiscal years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":5224770000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174687,"accession_number":"0000950170-25-029010","cik":1582313,"company_name":"Xenon Pharmaceuticals Inc.","ticker":"XENE","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["2.02","5.02","7.01","9.01"],"status":"ready","headline":"Xenon reports 2024 net loss $234.3M; CFO resigns; Phase 3 azetukalner FOS data due H2 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net loss for 2024 was $234.3M ($65.7M Q4), vs $182.4M in 2023; R&D spend rose to $210.4M.","Cash and marketable securities $754.4M as of Dec 31, 2024; sufficient to fund operations into 2027.","Phase 3 X-TOLE2/3 azetukalner FOS topline data expected H2 2025; Phase 3 MDD and bipolar depression trials advancing.","CFO Sherry Aulin resigns effective June 30, 2025, for personal reasons; will advise through Aug 31, 2025.","Neurocrine collaboration milestone triggers $7.5M payment; Phase 1 study of Nav1.2/1.6 inhibitor initiated."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5224770000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174686,"accession_number":"0000950170-25-006495","cik":1582313,"company_name":"Xenon Pharmaceuticals Inc.","ticker":"XENE","form_type":"8-K","filed_at":"2025-01-17T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Xenon Pharmaceuticals CCO Christopher Von Seggern departs; consulting agreement through May 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Christopher Von Seggern ceased as Chief Commercial Officer on January 17, 2025.","Separation Agreement provides severance per 2020 offer letter and 2024 annual bonus.","Consulting Agreement through May 1, 2025; equity awards continue vesting until then.","No replacement named for the CCO role."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":5224770000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191651,"accession_number":"0000950170-24-125374","cik":1582313,"company_name":"Xenon Pharmaceuticals Inc.","ticker":"XENE","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Xenon Q3 2024 net loss $62.8M; X-TOLE2 topline data expected H2 2025; COO appointed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $62.8M for Q3 2024, compared to $48.5M in Q3 2023; R&D expenses rose to $57.0M.","Cash and marketable securities $803.3M as of Sep 30, 2024; cash runway expected into 2027.","Phase 3 X-TOLE2 focal onset seizure study topline data anticipated in H2 2025.","Phase 3 MDD study X-NOVA2 expected to initiate by end of 2024.","Appointed Matt Ronsheim as COO, new senior executive; early-stage pipeline targeting multiple INDs in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.17,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5224770000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208113,"accession_number":"0000950170-24-093933","cik":1582313,"company_name":"Xenon Pharmaceuticals Inc.","ticker":"XENE","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Xenon reports Q2 net loss of $57.9M; cash $850.6M; Phase 3 epilepsy data H2 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for Q2 2024 was $57.9M, compared to $47.5M in Q2 2023.","Cash and marketable securities $850.6M as of June 30, 2024, down from $930.9M at Dec 31, 2023; cash runway into 2027.","Phase 3 X-TOLE2 top-line FOS data anticipated H2 2025; MDD Phase 3 study to start H2 2024.","R&D expenses $49.7M (Q2 2024) vs $44.0M (Q2 2023); G&A $19.4M vs $11.6M.","Pre-clinical Kv7 and Nav1.7 candidates advancing; multiple INDs expected in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.36,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5224770000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225674,"accession_number":"0000950170-24-069318","cik":1582313,"company_name":"Xenon Pharmaceuticals Inc.","ticker":"XENE","form_type":"8-K","filed_at":"2024-06-05T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Shareholders approve all proposals at annual meeting including 5.2M share increase to equity plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 8 director nominees elected, e.g., Dawn Svoronos 61.5M For vs 4.5M Against; broker non-votes 2.6M.","Say-on-pay advisory vote approved: 64.0M For, 2.0M Against, 0.01M abstain.","Equity plan amendments approved to increase share reserve by 5,200,000 common shares: 63.1M For, 2.8M Against.","KPMG LLP appointed as independent auditor for 2024: 66.7M For, 1.8M Withheld.","Auditor remuneration authority approved: 65.7M For, 0.39M Against, 0.01M Abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":5224770000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225673,"accession_number":"0000950170-24-056940","cik":1582313,"company_name":"Xenon Pharmaceuticals Inc.","ticker":"XENE","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Xenon Q1 net loss $47.9M; MDD Phase 3 on track for H2 2024 start","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $47.9M for Q1 2024, up from $41.7M in Q1 2023; cash and securities $885.4M.","R&D expenses rose to $44.3M from $39.5M, driven by azetukalner manufacturing and personnel costs.","Phase 3 MDD program to start H2 2024 after successful FDA interactions; X-TOLE2 enrollment completion expected late 2024 to early 2025.","WHO and USAN approved 'azetukalner' as generic name for XEN1101, a Kv7 potassium channel opener.","Other income increased to $11.5M from $7.6M on higher interest; cash expected to fund operations into 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.62,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5224770000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225672,"accession_number":"0000950170-24-046023","cik":1582313,"company_name":"Xenon Pharmaceuticals Inc.","ticker":"XENE","form_type":"8-K","filed_at":"2024-04-19T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Xenon Pharmaceuticals chair Simon Pimstone and director Mohammad Azab not standing for re-election","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Chair Simon Pimstone and board member Mohammad Azab will not stand for re-election at 2024 annual meeting.","Both directors will continue to serve until the AGM; departures are not due to any disagreement with company.","No replacements announced yet; board size and composition will change after AGM."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5224770000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244826,"accession_number":"0000950170-24-028784","cik":1582313,"company_name":"Xenon Pharmaceuticals Inc.","ticker":"XENE","form_type":"8-K","filed_at":"2024-03-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Xenon sets June 4, 2024 annual meeting; record date April 5","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual meeting of shareholders scheduled for June 4, 2024.","Record date for notice and voting is April 5, 2024.","Common shares are the only securities entitled to vote.","Notice-and-access not used for registered or non-registered investors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":5224770000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244825,"accession_number":"0000950170-24-023080","cik":1582313,"company_name":"Xenon Pharmaceuticals Inc.","ticker":"XENE","form_type":"8-K","filed_at":"2024-02-29T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Xenon Pharma reports FY2023 net loss $182.4M, cash $930.9M; XEN1101 Phase 3 on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $44.7M in Q4 2023 and $182.4M for FY2023, vs $37.4M and $125.4M in 2022.","R&D expenses $41.1M in Q4, $167.5M for FY2023, driven by XEN1101 Phase 3 epilepsy trials.","Cash and marketable securities $930.9M as of Dec 31, 2023; expected runway into 2027.","X-TOLE2 Phase 3 epilepsy patient enrollment expected to complete late 2024 to early 2025.","End-of-Phase 2 meeting with FDA for XEN1101 in major depressive disorder planned in April 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.73,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5224770000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}